![European Commission approves Tofersen as treatment for ALS-SOD1](https://backend.tricals.org/wp-content/uploads/2024/05/lab-550x456.jpg)
European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen.…
![Amylyx terminates open-label extension of the PHOENIX study](https://backend.tricals.org/wp-content/uploads/2024/05/pexels-mikhail-nilov-8851727-275x170.jpg)
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label…
![Meet the centre – Torino ALS Center (University of Torino)](https://backend.tricals.org/wp-content/uploads/2024/04/molinette-hospital-main-entrance-275x170.jpg)
Meet the centre – Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe.…
![Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets](https://backend.tricals.org/wp-content/uploads/2024/04/amylyx-1024x510-1-275x170.jpeg)
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug…
![Results of TUDCA-study: No effect of investigated compound](https://backend.tricals.org/wp-content/uploads/2024/03/tudca-logo-circle-e1574686822838-275x170.png)
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study,…
![Amylyx: no effect after analyzing phase 3 study](https://backend.tricals.org/wp-content/uploads/2022/10/amylyx--e1665046295146-275x170.jpeg)
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study.…
![Tofersen receives positive opinion from CHMP (EMA)](https://backend.tricals.org/wp-content/uploads/2024/02/TD-015-275x170.jpg)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European…
![Results ADORE study: no effect of medication](https://backend.tricals.org/wp-content/uploads/2024/01/1654154249240-275x170.jpeg)
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE…
![34th International Symposium on ALS/MND](https://backend.tricals.org/wp-content/uploads/2023/12/DSC01528-275x170.jpg)
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all…
![3FM Serious Request takes action for ALS Foundation Netherlands](https://backend.tricals.org/wp-content/uploads/2023/12/lock-me-out-ALS-1-1-275x170.jpg)
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during…